BIOMAT Database Logo BIOMAT Database Logo

Interleukin-2 and regulatory T cells in graft-versus-host disease. 2011

John Koreth, and Ken-ichi Matsuoka, and Haesook T Kim, and Sean M McDonough, and Bhavjot Bindra, and Edwin P Alyea, and Philippe Armand, and Corey Cutler, and Vincent T Ho, and Nathaniel S Treister, and Don C Bienfang, and Sashank Prasad, and Dmitrios Tzachanis, and Robin M Joyce, and David E Avigan, and Joseph H Antin, and Jerome Ritz, and Robert J Soiffer
Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA 02215, USA. john_koreth@dfci.harvard.edu

BACKGROUND Dysfunction of regulatory T (Treg) cells has been detected in diverse inflammatory disorders, including chronic graft-versus-host disease (GVHD). Interleukin-2 is critical for Treg cell growth, survival, and activity. We hypothesized that low-dose interleukin-2 could preferentially enhance Treg cells in vivo and suppress clinical manifestations of chronic GVHD. METHODS In this observational cohort study, patients with chronic GVHD that was refractory to glucocorticoid therapy received daily low-dose subcutaneous interleukin-2 (0.3×10(6), 1×10(6), or 3×10(6) IU per square meter of body-surface area) for 8 weeks. The end points were safety and clinical and immunologic response. After a 4-week hiatus, patients with a response could receive interleukin-2 for an extended period. RESULTS A total of 29 patients were enrolled. None had progression of chronic GVHD or relapse of a hematologic cancer. The maximum tolerated dose of interleukin-2 was 1×10(6) IU per square meter. The highest dose level induced unacceptable constitutional symptoms. Of the 23 patients who could be evaluated for response, 12 had major responses involving multiple sites. The numbers of CD4+ Treg cells were preferentially increased in all patients, with a peak median value, at 4 weeks, that was more than eight times the baseline value (P<0.001), without affecting CD4+ conventional T (Tcon) cells. The Treg:Tcon ratio increased to a median of more than five times the baseline value (P<0.001). The Treg cell count and Treg:Tcon ratio remained elevated at 8 weeks (P<0.001 for both comparisons with baseline values), then declined when the patients were not receiving interleukin-2. The increased numbers of Treg cells expressed the transcription factor forkhead box P3 (FOXP3) and could inhibit autologous Tcon cells. Immunologic and clinical responses were sustained in patients who received interleukin-2 for an extended period, permitting the glucocorticoid dose to be tapered by a mean of 60% (range, 25 to 100). CONCLUSIONS Daily low-dose interleukin-2 was safely administered in patients with active chronic GVHD that was refractory to glucocorticoid therapy. Administration was associated with preferential, sustained Treg cell expansion in vivo and amelioration of the manifestations of chronic GVHD in a substantial proportion of patients. (Funded by a Dana-Farber Dunkin' Donuts Rising Star award and others; ClinicalTrials.gov number, NCT00529035.).

UI MeSH Term Description Entries
D007376 Interleukin-2 A soluble substance elaborated by antigen- or mitogen-stimulated T-LYMPHOCYTES which induces DNA synthesis in naive lymphocytes. IL-2,Lymphocyte Mitogenic Factor,T-Cell Growth Factor,TCGF,IL2,Interleukin II,Interleukine 2,RU 49637,RU-49637,Ro-23-6019,Ro-236019,T-Cell Stimulating Factor,Thymocyte Stimulating Factor,Interleukin 2,Mitogenic Factor, Lymphocyte,RU49637,Ro 23 6019,Ro 236019,Ro236019,T Cell Growth Factor,T Cell Stimulating Factor
D007958 Leukocyte Count The number of WHITE BLOOD CELLS per unit volume in venous BLOOD. A differential leukocyte count measures the relative numbers of the different types of white cells. Blood Cell Count, White,Differential Leukocyte Count,Leukocyte Count, Differential,Leukocyte Number,White Blood Cell Count,Count, Differential Leukocyte,Count, Leukocyte,Counts, Differential Leukocyte,Counts, Leukocyte,Differential Leukocyte Counts,Leukocyte Counts,Leukocyte Counts, Differential,Leukocyte Numbers,Number, Leukocyte,Numbers, Leukocyte
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004351 Drug Resistance Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration. Resistance, Drug
D005260 Female Females
D005938 Glucocorticoids A group of CORTICOSTEROIDS that affect carbohydrate metabolism (GLUCONEOGENESIS, liver glycogen deposition, elevation of BLOOD SUGAR), inhibit ADRENOCORTICOTROPIC HORMONE secretion, and possess pronounced anti-inflammatory activity. They also play a role in fat and protein metabolism, maintenance of arterial blood pressure, alteration of the connective tissue response to injury, reduction in the number of circulating lymphocytes, and functioning of the central nervous system. Glucocorticoid,Glucocorticoid Effect,Glucorticoid Effects,Effect, Glucocorticoid,Effects, Glucorticoid
D006086 Graft vs Host Disease The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION. Graft-Versus-Host Disease,Homologous Wasting Disease,Runt Disease,Graft-vs-Host Disease,Disease, Graft-Versus-Host,Disease, Graft-vs-Host,Disease, Homologous Wasting,Disease, Runt,Diseases, Graft-Versus-Host,Diseases, Graft-vs-Host,Graft Versus Host Disease,Graft-Versus-Host Diseases,Graft-vs-Host Diseases

Related Publications

John Koreth, and Ken-ichi Matsuoka, and Haesook T Kim, and Sean M McDonough, and Bhavjot Bindra, and Edwin P Alyea, and Philippe Armand, and Corey Cutler, and Vincent T Ho, and Nathaniel S Treister, and Don C Bienfang, and Sashank Prasad, and Dmitrios Tzachanis, and Robin M Joyce, and David E Avigan, and Joseph H Antin, and Jerome Ritz, and Robert J Soiffer
Regulatory T cells in graft-versus-host disease.
March 2012, The New England journal of medicine,
John Koreth, and Ken-ichi Matsuoka, and Haesook T Kim, and Sean M McDonough, and Bhavjot Bindra, and Edwin P Alyea, and Philippe Armand, and Corey Cutler, and Vincent T Ho, and Nathaniel S Treister, and Don C Bienfang, and Sashank Prasad, and Dmitrios Tzachanis, and Robin M Joyce, and David E Avigan, and Joseph H Antin, and Jerome Ritz, and Robert J Soiffer
Regulatory T cells in graft-versus-host disease.
March 2012, The New England journal of medicine,
John Koreth, and Ken-ichi Matsuoka, and Haesook T Kim, and Sean M McDonough, and Bhavjot Bindra, and Edwin P Alyea, and Philippe Armand, and Corey Cutler, and Vincent T Ho, and Nathaniel S Treister, and Don C Bienfang, and Sashank Prasad, and Dmitrios Tzachanis, and Robin M Joyce, and David E Avigan, and Joseph H Antin, and Jerome Ritz, and Robert J Soiffer
Regulatory T cells in graft-versus-host disease.
August 2006, Springer seminars in immunopathology,
John Koreth, and Ken-ichi Matsuoka, and Haesook T Kim, and Sean M McDonough, and Bhavjot Bindra, and Edwin P Alyea, and Philippe Armand, and Corey Cutler, and Vincent T Ho, and Nathaniel S Treister, and Don C Bienfang, and Sashank Prasad, and Dmitrios Tzachanis, and Robin M Joyce, and David E Avigan, and Joseph H Antin, and Jerome Ritz, and Robert J Soiffer
Editorial: Regulatory T cells in graft versus host disease.
January 2022, Frontiers in immunology,
John Koreth, and Ken-ichi Matsuoka, and Haesook T Kim, and Sean M McDonough, and Bhavjot Bindra, and Edwin P Alyea, and Philippe Armand, and Corey Cutler, and Vincent T Ho, and Nathaniel S Treister, and Don C Bienfang, and Sashank Prasad, and Dmitrios Tzachanis, and Robin M Joyce, and David E Avigan, and Joseph H Antin, and Jerome Ritz, and Robert J Soiffer
CD4+CD25+ regulatory T cells and graft-versus-host disease.
January 2006, Seminars in hematology,
John Koreth, and Ken-ichi Matsuoka, and Haesook T Kim, and Sean M McDonough, and Bhavjot Bindra, and Edwin P Alyea, and Philippe Armand, and Corey Cutler, and Vincent T Ho, and Nathaniel S Treister, and Don C Bienfang, and Sashank Prasad, and Dmitrios Tzachanis, and Robin M Joyce, and David E Avigan, and Joseph H Antin, and Jerome Ritz, and Robert J Soiffer
Regulatory T cells and IL-17-producing cells in graft-versus-host disease.
July 2011, Immunotherapy,
John Koreth, and Ken-ichi Matsuoka, and Haesook T Kim, and Sean M McDonough, and Bhavjot Bindra, and Edwin P Alyea, and Philippe Armand, and Corey Cutler, and Vincent T Ho, and Nathaniel S Treister, and Don C Bienfang, and Sashank Prasad, and Dmitrios Tzachanis, and Robin M Joyce, and David E Avigan, and Joseph H Antin, and Jerome Ritz, and Robert J Soiffer
Interleukin 2 prevents graft-versus-host disease while preserving the graft-versus-leukemia effect of allogeneic T cells.
August 1990, Proceedings of the National Academy of Sciences of the United States of America,
John Koreth, and Ken-ichi Matsuoka, and Haesook T Kim, and Sean M McDonough, and Bhavjot Bindra, and Edwin P Alyea, and Philippe Armand, and Corey Cutler, and Vincent T Ho, and Nathaniel S Treister, and Don C Bienfang, and Sashank Prasad, and Dmitrios Tzachanis, and Robin M Joyce, and David E Avigan, and Joseph H Antin, and Jerome Ritz, and Robert J Soiffer
Interleukin-27 Enforces Regulatory T Cell Functions to Prevent Graft-versus-Host Disease.
January 2020, Frontiers in immunology,
John Koreth, and Ken-ichi Matsuoka, and Haesook T Kim, and Sean M McDonough, and Bhavjot Bindra, and Edwin P Alyea, and Philippe Armand, and Corey Cutler, and Vincent T Ho, and Nathaniel S Treister, and Don C Bienfang, and Sashank Prasad, and Dmitrios Tzachanis, and Robin M Joyce, and David E Avigan, and Joseph H Antin, and Jerome Ritz, and Robert J Soiffer
Therapeutic use of regulatory T cells for graft-versus-host disease.
October 2019, British journal of haematology,
John Koreth, and Ken-ichi Matsuoka, and Haesook T Kim, and Sean M McDonough, and Bhavjot Bindra, and Edwin P Alyea, and Philippe Armand, and Corey Cutler, and Vincent T Ho, and Nathaniel S Treister, and Don C Bienfang, and Sashank Prasad, and Dmitrios Tzachanis, and Robin M Joyce, and David E Avigan, and Joseph H Antin, and Jerome Ritz, and Robert J Soiffer
TCR transgenic regulatory T cells prevent lethal graft-versus-host disease.
January 2001, Transplantation proceedings,
Copied contents to your clipboard!